$Provention Bio, Inc(PRVB)$ TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
由FDA批准的Tzield™(teplizumab-MZWV)是第一种也是唯一的治疗方法,该治疗方法延迟了8岁及8岁以上的成人和儿科患者的第3期1型糖尿病(T1D)的发作。
精彩评论